SCHEMBL4352995

SCHEMBL4352995

CC(=O)N1CCC(Nc2ncc(C(=O)c3ccc(C)cc3)c(N)n2)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 17/20 0.69
CDK1 P06493 16/20 0.69
CDK4 P11802 15/20 0.69
CCND1 P24385 15/20 0.69
SYK P43405 2/20 0.50
CCNA2 P20248 2/20 0.48
CCNA1 P78396 2/20 0.48
CASK O14936 1/20 0.47
ROCK2 O75116 1/20 0.47
CDKL5 O76039 1/20 0.47
STK10 O94804 1/20 0.47
CDK14 O94921 1/20 0.47
ABL1 P00519 1/20 0.47
EGFR P00533 1/20 0.47
MAK P20794 1/20 0.47
CDK11B P21127 1/20 0.47
TTK P33981 1/20 0.47
CLK1 P49759 1/20 0.47
CLK2 P49760 1/20 0.47
CLK3 P49761 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348098 0.91 CDK1 (0.68) CDK2CDK1CDK4CCND1SYK
SCHEMBL4359985 0.91 CDK1 (0.66) CDK2CDK1CDK4CCND1SYK
SCHEMBL4348656 0.89 CDK1 (0.72) CDK2CDK1CDK4CCND1CASK
SCHEMBL4361250 0.86 CDK2 (0.70) CDK2CDK1CDK4CCND1SYK
SCHEMBL5737760 0.85 CDK1 (0.53) CDK2CDK1CDK4CCND1CASK
SCHEMBL27688682 0.85 CDK1 (0.53) CDK2CDK1CDK4CCND1CASK
SCHEMBL4347333 0.84 CDK1 (0.80) CDK2CDK1CDK4CCND1CASK
SCHEMBL27688686 0.83 CDK1 (0.52) CDK2CDK1CDK4CCND1CASK
SCHEMBL4348425 0.82 CDK1 (1.00) CDK2CDK1CDK4CCND1CASK
SCHEMBL4355622 0.82 CDK1 (0.62) CDK2CDK1CDK4CCND1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US claimed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK2 4/4885CDK1 6/4885CDK4 1/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK2 3/4885CDK1 6/4885CDK4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.